Zampilimab, designated as UCB-7858 or 2098280-42-1, represents a novel therapeutic agent targeting TGM2, a molecule involved in fat metabolism and conceivably implicated in various autoimmune disorders. This https://www.targetmol.com/compound/zampilimab